In this clip from Breast Cancer Breakthroughs, learn about how researchers are eyeing a new drug target called HER3. Results from a Phase 2 trial testing the antibody-drug conjugate HER3-DXd in metastatic breast cancer was presented at ASCO 2023 by Dr. Erika Hamilton. Here, Dr. Hamilton explains the encouraging results observed so far and the next steps to bring this drug closer to patients.
Dr. Erika Hamilton is a medical oncologist at the Sarah Cannon Research Institute
Kelsey Hampton, PhD is Senior Manager, Mission Communications at Susan G. Komen
Sign up for reminders about future episodes of Breast Cancer Breakthroughs here: [ Ссылка ]
Resources:
Antibody-drug conjugates:
[ Ссылка ]
Clinical Trials:
Phase 2 study of HER3-DXd in metastatic breast cancer (Recruiting): [ Ссылка ]
